10:11 AM EST - Afexa Life Sciences Inc. : announced promising results of a pilot clinical study investigating the effects of a new formulation, Dilexaponan(TM) (LIP-01) on cholesterol management. Dilexaponan is a proprietary polymolecular formulation isolated from botanical sources and developed and standardized using ChemBioPrint technology. Afexa Life Sciences Inc.
shares T.FXA are trading down $0.01 at $0.57.
